PharmaEssentia revenue and financials
$1,205.00Change from previous close: +2.55%Absolute change: +$30.00
In the fiscal year ended December 2025, PharmaEssentia reported revenue of $15.63B (+60.61% year over year). Net income was $5.05B, a net margin of 32.3%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +60.61%
- 2025 vs 2024
- Net income growth
- +70.13%
- 2025 vs 2024
- Net margin
- 32.3%
- 2024: 30.5%
Financial data
Amounts in millions of TWD; per-share values in TWD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Operating cash flow | 2,395 | 1,734 | 1,912 | 70.5 | 1,061 |
| Depreciation and amortization | 123 | 117 | 105 | 98.3 | 96.6 |
| Capital expenditure | -386 | -579 | -1,037 | -308 | -227 |
| Investing cash flow | -2,147 | -525 | -1,120 | -318 | -284 |
| Financing cash flow | 84.4 | -14.9 | 11.9 | -43.4 | -46.9 |
| Dividends paid | — | — | 0.0 | — | — |
| Debt issued | — | — | 67.7 | — | — |
| Debt repaid | -1.5 | -1.5 | -70.3 | -2,315 | -3.1 |
| Effect of exchange rates | -36.4 | 288 | 307 | -961 | 253 |
| Net change in cash | 332 | 1,194 | 804 | -291 | 731 |
| Free cash flow | 2,008 | 1,155 | 875 | -237 | 835 |